Holen Sie sich die Stockscreener-App
7.91
3.54%
-0.29
Handel nachbörslich:
7.86
-0.05
-0.63%
Vanda Pharmaceuticals Inc Aktie (VNDA) Neueste Nachrichten
Truist Financial Begins Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) - MarketBeat
Truist Securities Initiates Coverage on Vanda Pharmaceuticals (V - GuruFocus
Truist initiates Vanda Pharmaceuticals stock at buy on drug pipeline - Investing.com
Truist Initiates Vanda Pharmaceuticals at Buy With $18 Price Target - marketscreener.com
Vanda Pharmaceuticals (NASDAQ:VNDA) CMO Joakim Wijkstrom Sells 30,800 Shares - MarketBeat
Kevin Patrick Moran Sells 42,442 Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) Stock - MarketBeat
Insider Selling: Vanda Pharmaceuticals (NASDAQ:VNDA) SVP Sells 42,434 Shares of Stock - MarketBeat
Gunther Birznieks Sells 42,431 Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) Stock - MarketBeat
Insider Selling: Vanda Pharmaceuticals (NASDAQ:VNDA) CEO Sells 156,235 Shares of Stock - MarketBeat
Vanda Pharmaceuticals (VNDA) SVP sells 42,431 shares to cover RSU tax - Stock Titan
VNDA SEC FilingsVanda Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
Q1 Earnings Estimate for VNDA Issued By HC Wainwright - MarketBeat
VNDA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
FDA Grants Rare Hearing for Vanda Pharmaceuticals' (VNDA) Jet La - GuruFocus
Vanda Now Looks To Public Hearing For Hetlioz In Jet Lag Disorder After Multiple FDA Rejections - Stocktwits
After years of dispute with FDA, Vanda will get a public hearing for jet lag drug - Endpoints News
Vanda secures win in regulatory showdown as FDA agrees to review jet lag drug - The Business Journals
Vanda announces FDA grants landmark hearing for Hetlioz® in jet lag disorder, the first drug approval hearing in over 40 years - marketscreener.com
Vanda Pharmaceuticals Wins Rare FDA Hearing on HETLIOZ Application for Jet Lag - marketscreener.com
Vanda Pharmaceuticals (VNDA) Secures Rare FDA Hearing for Hetlio - GuruFocus
Vanda Announces FDA Grants Landmark Hearing for HETLIOZ in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years - Finviz
Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years - ChartMill
Vanda Pharmaceuticals (NASDAQ:VNDA) Share Price Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
[144] Vanda Pharmaceuticals Inc. SEC Filing - Stock Titan
VNDA Earnings History & Surprises | EPS & Revenue Results | VANDA PHARMACEUTICALS INC (NASDAQ:VNDA) - ChartMill
EMA Turns Down Vanda’s Iloperidone And Acadia’s Daybu, Backs 12 Others For EU Approval - Citeline News & Insights
Vanda Pharmaceuticals Receives Negative Opinion From European Medicines Agency's CHMP for Iloperidone - marketscreener.com
Vanda Pharmaceuticals to Participate in 2026 Citizens Life Sciences Conference - Intellectia AI
Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference - ChartMill
A Look At Vanda Pharmaceuticals (VNDA) Valuation After FDA Approval Of Bysanti For Bipolar I Disorder And Schizophrenia - simplywall.st
Vanda Pharmaceuticals price target raised to $17 from $14 at B. Riley - Yahoo Finance
Vanda Pharmaceuticals Inc. (VNDA) Stock Analysis: A Biotech Contender with Nearly 80% Upside Potential - DirectorsTalk Interviews
Vanda Pharmaceuticals Breaks Through With FDA Approval, Decision Date For Skin Drug - Benzinga
Vanda skin disorder drug accepted for FDA review - MSN
Vanda Pharmaceuticals Says US FDA Accepts Imsidolimab BLA for Rare Skin Disease - marketscreener.com
Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder - Asianet Newsable
B. Riley Adjusts Vanda Pharmaceuticals Price Target to $17 From $14, Maintains Buy Rating - marketscreener.com
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis - The Malaysian Reserve
Vanda Pharmaceuticals Seeks FDA Approval for Imsidolimab - Intellectia AI
Vanda Pharmaceuticals (VNDA) Gains on FDA Review Acceptance for Imsidolimab - GuruFocus
Vanda Pharmaceuticals Files BLA for Imsidolimab to Treat GPP - Intellectia AI
Vanda skin disorder drug accepted for FDA review (VNDA:NASDAQ) - Seeking Alpha
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics Lice - GuruFocus
Insider Sell: Tage Honore Sells 30,000 Shares of Vanda Pharmaceu - GuruFocus
Director Honore Tage sells 30,000 Vanda (NASDAQ: VNDA) shares at $8.03 - Stock Titan
What's Going On With Vanda Pharma Stock Tuesday? - Bitget
VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains? - Stocktwits
Vanda Pharmaceuticals stock price target raised to $24 by H.C. Wainwright on FDA approval - Investing.com UK
Insider files Form 144 to sell 30,000 Vanda Pharma shares (VNDA) - Stock Titan
Vanda Pharmaceuticals stock jumps 41% on Bysanti FDA approval filing as analysts weigh uptake risk - Bez Kabli
Vanda Pharmaceuticals scores second FDA approval in 2 months - The Business Journals
Vanda Pharmaceuticals: Soaring On Bysanti Approval, But You Shouldn't Feel Dizzy (VNDA) - Seeking Alpha
Vanda Pharmaceuticals surges as FDA approves Bysanti for bipolar I disorder and schizophrenia - Quiver Quantitative
Vanda Pharmaceuticals stock’s explosive rally may be more hype than substance - Invezz
Vanda, with FDA nod for Bysanti, gains 2nd new drug approval in as many months - Fierce Pharma
VNDA: HC Wainwright & Co. Raises Price Target to $24.00, Maintai - GuruFocus
Stock Movers: Deere, Veris Residential, Vanda Pharmaceuticals - Bloomberg
Vanda Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:VNDA) - MarketBeat
Vanda stock’s explosive rally may be more hype than substance - Invezz
FDA Approval Pushes Vanda Pharmaceuticals Shares Higher - StocksToTrade
Vanda Pharmaceuticals Soars with FDA Approval for Bysanti - timothysykes.com
Vanda Pharmaceuticals FDA Approval Dawns A New Era For Bipolar And Schizophrenia Treatment - Bitget
Vanda Pharmaceuticals (VNDA) Surges on FDA Approval of Bysanti - GuruFocus
Stock Market Today: Dow Jones, S&P500, Nasdaq Futures Decline After SC Strikes Down Trump's Emergency Tariffs— NVO, MSTR, VNDA In Focus (UPDATED) - Benzinga
Vanda Pharmaceuticals (VNDA) Stock: Jumps 44% After FDA Approves Second Drug in Two Months - Blockonomi
Vanda Wins FDA Approval for Bysanti Antipsychotic Therapy - TipRanks
Analyst Expectations For Vanda Pharmaceuticals's Future - Benzinga
Vanda Gains Branded Successor To Fanapt As US FDA Approves Another Antipsychotic - Citeline News & Insights
3.69%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):